Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Buzz on the Bullboards: Old favourites make their return

September is often seen as a “fresh start” for the markets, like a new year on the stock exchange, but this party was met with a serious hangover in the shape of poor performances among sectors that only just recently began to turn around. One ma...
Jonathon Brown | September 14, 2023 |

Buzz on the Bullboards: Stocks Making the Most of the Fall Season

Following news that it expects revenue for Q3 2021 to be at least $8 million, resulting in total revenue for the nine months ended September 30, 2021 of at least $22 million (twice as much as that period, last year), PyroGenesis Canada Inc. ( TSX-V.PYR , Forum ) announ...
Stockhouse Editorial | November 3, 2021 |

Novamind Selected by Merck to Advance Research for Treatment-Resistant Depression

Novamind’s subsidiary, Cedar Clinical Research, to serve as a key clinical research site Independent validation of the expertise and capabilities of Novamind in managing clinical trials Adds to established track record conducting research a...
Featured Submission | March 18, 2021 |

Aravive Shares Rise on Positive Patient Data from Phase 1b Ovarian Cancer Study

Shares of Aravive Inc. are trading higher after the firm posted positive data from the initial 12 patients enrolled in the Phase 1b portion of its study of AVB-500 used in the treatment of ovarian cancer. Today, in a late-breaking oral presentation at the European Soc...
Streetwise Reports | September 30, 2019 |

Mersana Therapeutics Trades 60% Higher on Positive Phase 1 Ovarian Cancer Trial Data

Shares of Mersana Therapeutics reached a new 52-week high price after the company reported positive interim data from the expanded portion of its Phase 1 study of XMT-1536 for treatment of ovarian cancer. Clinical-stage biopharmaceutical company Mersana Therapeuti...
Streetwise Reports | May 28, 2020 |

Iterum Therapeutics Shares Double After Completing Enrollment in Phase 3 Antibiotic Trial

Iterum Therapeutics shares traded more than 100% higher after the company reported that it has completed enrollment in its Phase 3 SURE 1 clinical study of oral sulopenem for treatment of uncomplicated urinary tract infections. The firm expects to receive topline data results ...
Streetwise Reports | December 30, 2019 |

Apple's (NASDAQ: AAPL) bet on Liquidmetal about to pay off?

Apple Inc. ( NASDAQ: AAPL , Stock Forum ) loves to think of lucrative new uses for other people's bright ideas. For instance, the original iPod wouldn't have been possible without Toshiba's innovative 1.8-inch hard drive. And when Steve Jobs learned about Gorilla Glass...
David Zeiler | October 28, 2012 |

Why Did ImmunoGen Plummet 32%?

This biotechnology company, which focuses on the treatment of cancer, received some feedback from the FDA that upset investors on Wednesday. ImmunoGen Inc.'s (IMGN:NASDAQ) shares closed down 32.06% on the NASDAQ Wednesday after announcing the United States ...
Streetwise Reports | May 21, 2019 |

Novamind’s Trial Site for Merck Another Example Of Its Leadership in Mental Health

Novamind’s clinics and clinical research capabilities are already well established to bring alternative mental health therapies, including psychedelic medicine, to market. One of the world’s largest pharmaceutical companies has selected ...
Featured Submission | March 24, 2021 |

Two Stock-Moving Catalysts Expected in March for Biopharma

These events for Axsome Therapeutics are described in an H.C. Wainwright & Co. report. In a Feb. 24 research note, H.C. Wainwright & Co. analyst Ram Selvaraju reported that Axsome Therapeutics Inc. (AXSM:NASDAQ) finished patient enrollment for its INTERCEP...
Streetwise Reports | February 26, 2020 |
1 2 3 4 5